ReviewDrug design, development and therapy2022

Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status.

Teesha Downton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.